- Home
- VTVT vs CBUS Comparison
VTVT vs CBUS Comparison
Compare VTVT & CBUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VTVT
- CBUS
- Stock Information
- Founded
- VTVT 2015
- CBUS 2010
- Country
- VTVT United States
- CBUS United States
- Employees
- VTVT N/A
- CBUS N/A
- Industry
- VTVT Biotechnology: Pharmaceutical Preparations
- CBUS Agricultural Chemicals
- Sector
- VTVT Health Care
- CBUS Industrials
- Exchange
- VTVT Nasdaq
- CBUS Nasdaq
- Market Cap
- VTVT 56.7M
- CBUS 65.3M
- IPO Year
- VTVT 2015
- CBUS 2017
- Fundamental
- Price
- VTVT $16.67
- CBUS $1.55
- Analyst Decision
- VTVT Strong Buy
- CBUS Strong Buy
- Analyst Count
- VTVT 2
- CBUS 3
- Target Price
- VTVT $35.50
- CBUS $22.00
- AVG Volume (30 Days)
- VTVT 5.3K
- CBUS 369.3K
- Earning Date
- VTVT 05-15-2025
- CBUS 05-08-2025
- Dividend Yield
- VTVT N/A
- CBUS N/A
- EPS Growth
- VTVT N/A
- CBUS N/A
- EPS
- VTVT N/A
- CBUS N/A
- Revenue
- VTVT $17,000.00
- CBUS $4,751,000.00
- Revenue This Year
- VTVT N/A
- CBUS $32.97
- Revenue Next Year
- VTVT N/A
- CBUS $66.40
- P/E Ratio
- VTVT N/A
- CBUS N/A
- Revenue Growth
- VTVT N/A
- CBUS 104.78
- 52 Week Low
- VTVT $12.12
- CBUS $1.40
- 52 Week High
- VTVT $26.99
- CBUS $11.75
- Technical
- Relative Strength Index (RSI)
- VTVT 40.48
- CBUS 35.12
- Support Level
- VTVT $15.92
- CBUS $2.16
- Resistance Level
- VTVT $16.70
- CBUS $3.40
- Average True Range (ATR)
- VTVT 0.98
- CBUS 0.36
- MACD
- VTVT -0.37
- CBUS -0.12
- Stochastic Oscillator
- VTVT 16.47
- CBUS 2.12
About VTVT vTv Therapeutics Inc.
vTv Therapeutics Inc is a clinical stage biopharmaceutical company focused on the development of orally administered treatments for metabolic and inflammatory diseases to minimize their long-term complications and improve the lives of patients. Its product pipeline include TTP399, TTP273, HPP737, HPP593, Azeliragon, HPP971, HPP3033, and TTP-RA.
About CBUS Cibus Inc.
Cibus Inc is a biotechnology company. The company develops and commercializes a proprietary gene-editing technology, Rapid Trait Development System that integrates crop specific cell biology platforms with a series of gene editing technologies. The company's primary business is the development of plant traits that help address specific productivity or yield challenges in farming such as traits addressing plant agronomy, disease, insects, weeds, nutrient-use, or the climate.